Immune System Modifications Induced in a Mouse Model of Chronic Exposure to90Sr

2016 ◽  
Vol 185 (3) ◽  
pp. 267-284 ◽  
Author(s):  
Nicholas Synhaeve ◽  
Stefania Musilli ◽  
Johanna Stefani ◽  
Nour Nicolas ◽  
Olivia Delissen ◽  
...  
2014 ◽  
Vol 59 ◽  
pp. 8-15 ◽  
Author(s):  
Carlos Gómez-Gallego ◽  
Rafael Frias ◽  
Gaspar Pérez-Martínez ◽  
María José Bernal ◽  
María Jesús Periago ◽  
...  

2014 ◽  
Vol 69 ◽  
pp. 320-329 ◽  
Author(s):  
Celeste Di Paolo ◽  
Ingrid Reverte ◽  
Maria Teresa Colomina ◽  
José L. Domingo ◽  
Mercedes Gómez

2021 ◽  
Vol 9 (Suppl 1) ◽  
pp. A22.1-A22
Author(s):  
C Reitinger ◽  
F Nimmerjahn

BackgroundRecent findings in cancer immunotherapy have reinforced the hypothesis that the immune system is able to control most cancers. Immunomodulatory antibodies can enhance immune responses, having the potential to generate anti-cancer immunity.1–4Materials and MethodsMost current studies addressing this question are performed in murine mouse model systems or use in vitro culture systems, which do not reflect the human in vivo situation, potentially leading to results that cannot be fully translated into human cancer therapy. Therefore, it is necessary to establish a new mouse model, which allows the study of cancer immunotherapy in the context of a human immune system. We focused on the establishment of a humanized mouse model, in which different immunomodulatory antibodies can be tested in the presence of a human immune system.ResultsFirst experiments concerning the suitability to test immunomodulatory antibodies in the humanized mouse model, revealed that effects of checkpoint-control antibody a-CTLA-4 were similar to the effects seen in patients of clinical studies. To analyse the anti-tumor activities of immunomodulatory antibodies in vivo we are establishing a human melanoma-like tumor model in humanized mice.ConclusionsThis enables us to test the efficacy of immunomodulatory agonistic antibodies (such as CP-870,893) and checkpoint control antibodies (such as anti-CTLA-4) in eliminating a melanoma-like tumor. Furthermore, parameters like tumor infiltrating human cells und cytokine/chemokine production can be analysed.ReferencesSchuster M, Nechansky A, Loibner H. Cancer immunotherapy. Biotechnol J 2006;1:138–147.Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature rev 2011;480:480–489.Finn OJ. Immuno-oncology: understanding the function and dysfunction of the immune system in cancer. Annals of Oncology 2012;23:vii6–vii9.Langer LF, Clay TM, Morse MA. Update on anti-CTLA-4 in clinical trials. Expert Opin Biol Ther 2007;8:1245–1256.Disclosure InformationC. Reitinger: None. F. Nimmerjahn: None.


2021 ◽  
Author(s):  
Wei Zhou ◽  
Kin-hoe Chow ◽  
Rory Geyer ◽  
Paola Peshkepija ◽  
Elizabeth Fleming ◽  
...  

Human gut microbiota has co-evolved with human, and plays important roles in regulating the development and functioning of the host immune system. To study the human-specific microbiome-immunune interaction in an animal model is challenging as the animal model needs to capture both the human-specific immune functions and the human-specific microbiome composition. Here we combined two widely-used humanization procedures to generate a humanized mouse model (HMA-huCD34) with functional human leukocytes developed from engrafted huCD34+ cells and human fecal microbes introduced through fecal microbiota transplantation, and investigated how the two introduced human components interact. We found that the engrafted human leukocytes are resilient to the transplanted human microbes, while reciprocally the transplanted microbial community in the huCD34 mice was significantly different from mice without a humanized immune system. By tracking the colonization of human fecal Bacteroides strains in the mouse gut, we found that the composition of the strain population changes over time, the trajectory of which depends upon the type of mouse. On the other hand, different from Bacteroides, Akkermansia muciniphila exhibited consistent and rapid fixation of a single donor strain in all tested mice, suggesting strong purifying selection common to all mouse types. Our prospect study illustrated the complex interactions between the transplanted microbiome and different host factors, and suggested that the humanized mouse model may not faithfully reproduce the human-specific microbiome-immune interaction.


1986 ◽  
Vol 5 (3) ◽  
pp. 154-156
Author(s):  
P. G. Thiel

Fungal contamination of agricultural products can prove to be harmful to humans and domestic animals as these fungi produce a variety of mycotoxins which can eventually occur in food. Acute intoxications with mycotoxins occur regularly in farm animals but, fortunately, are infrequently observed in humans. However, the chronic exposure of humans to mycotoxins occurs regularly. Such exposures are potentially teratogenic and carcmogenic and can suppress the immune system. It is presently impossible to establish safe levels of exposure for most mycotoxins due to scanty epidemiological data and insufficient observations on experimental animals. With respect to aflatoxin all available data point to a real health risk. Risk analysis based on epidemiological observations shows that the liver-cancer risk for individuals in South Africa is potentially increased by continued exposure to the present legally permitted level of aflatoxin in food.


2019 ◽  
Vol 156 (3) ◽  
pp. S104-S105
Author(s):  
Adrian Gomez-Nguyen ◽  
Ludovica F. Buttò ◽  
Abigail R. Basson ◽  
Theresa Pizarro ◽  
Fabio Cominelli

2019 ◽  
Vol 247 ◽  
pp. 953-963 ◽  
Author(s):  
Yanyi Xu ◽  
Wanjun Wang ◽  
Ji Zhou ◽  
Minjie Chen ◽  
Xingke Huang ◽  
...  

2019 ◽  
Vol 11 (3) ◽  
pp. 632-635
Author(s):  
Raziye Piranlioglu ◽  
Hasan Korkaya ◽  
Khaled A. Hassan

Sign in / Sign up

Export Citation Format

Share Document